As physicians and health policy experts debate the merits of Aduhelm, the first new drug for Alzheimer’s disease approved in 18 years, patients want to know: “Will this medication help me — and how much?”
A rigorous meta-analysis of randomized clinical trials (RCTs) that compared the effects of medical therapies alone with medical therapies plus revascularization in patients with stable ischemic heart disease (SIHD) was presented at EuroPCR on May 18, 2021.
Abbott today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual antiplatelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – for patients with high bleeding risk (HBR).
Researchers at Lund University in Sweden can now show that a new examination method identifies high-risk plaques in the blood vessels surrounding the heart, that cannot be seen solely with traditional angiograms. This type of plaque, rich in fat, could potentially cause recurring heart attacks in patients with heart disease. The study is published in […]
A new approach to the guidance, planning, and conducting of heart bypass surgery is being tested on patients for the first time in a clinical trial coordinated by a high-level research team at NUI Galway.
Long QT syndrome (LQTS), caused by an ion channel-related gene mutation, is a malignant heart disease with a clinical course of a high incidence of ventricular fibrillation and sudden cardiac death in the young.
The British Heart Foundation is funding a trial for an experimental drug that could prevent the life-threatening blood clots that are seen in the lungs of the patients with COVID-19 or those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Physician-scientists specializing in heart failure wanted to know: if their heart transplant patients contract COVID-19, would they have a different experience than the general public or others who are also immunosuppressed?
A group of over 120 researchers from various institutions across Europe has performed the first genome-wide association study to reveal host genetic factors that may contribute to respiratory failure in cases of coronavirus disease 209 (COVID-19).
Despite concerns expressed by some experts, common high blood pressure drugs did not increase the risk of contracting COVID-19 – or of developing severe disease – in a study of 12,594 patients.
Stay Up-To-Date on jobs and industry news.
Sign up for the CathLab.com newsletter today!